Regeneron expands Ebola supply agreement by $270 million

• Regeneron Pharmaceuticals extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA), adding approximately $270 million in value for additional supplies of its FDA-approved Ebola treatment Inmazeb.
• The company expects to supply Inmazeb doses to the U.S. government through 2031, expanding an existing procurement relationship established in 2020.
• Separately, Regeneron is advancing investigational maftivimab into the PARTNERS clinical trial for Bundibugyo virus disease in the Democratic Republic of the Congo, following encouraging laboratory and animal studies.

Regeneron Pharmaceuticals (NASDAQ:REGN) announced a $270 million extension of its agreement with the Biomedical Advanced Research and Development Authority to supply additional doses of Inmazeb for U.S. preparedness against Ebola outbreaks.

The expanded agreement builds on the original 2020 procurement contract, with Regeneron expecting to deliver additional treatments through 2031 and receive approximately $270 million in payments.

“Maintaining a ready supply of Inmazeb is exactly the kind of preparedness this country needs for the threats we can already see on the horizon,” said Regeneron President and Chief Executive Officer Leonard Schleifer.

Inmazeb combines three monoclonal antibodies—atoltivimab, maftivimab and odesivimab-ebgn—and is FDA-approved to treat infections caused by Orthoebolavirus zairense in adults and children, including newborns born to infected mothers.

Regeneron is separately adding investigational maftivimab to the PARTNERS clinical trial to evaluate its potential against Bundibugyo virus disease during the ongoing outbreak in the Democratic Republic of the Congo.

Laboratory and non-human primate studies demonstrated activity against Bundibugyo virus, although the findings remain available only as a preprint awaiting peer review and have not established clinical efficacy in humans.

The PARTNERS trial is sponsored by the World Health Organization and coordinated internationally by the University of Oxford's Pandemic Sciences Institute, while no treatments are currently approved specifically for Bundibugyo virus disease.